Skip to main content

Advertisement

SpringerLink
Log in

Procalcitonin can be used as a marker of premature atherosclerosis in acromegaly

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

The objective of the study was to evaluate arterial morphologic changes of early atherosclerosis and changes in procalcitonin (PCT) levels in patients with acromegaly according to disease activity. Thirty-three active and 20 inactive acromegaly patients followed at Endocrinology-Metabolism out-patient clinic of Cerrahpasa Medical Faculty between 2004 and 2008 were included in the study. Twenty gender and age matched healthy subjects were included as the control group. Intima-media thickness (IMT) of the carotid arteries was measured by ultrasonography. Blood was drawn for biochemical tests and the serum concentrations of C-reactive protein (CRP) and PCT. Intergroup analysis revealed no significant differences between Growth hormone (GH), insulin like growth factor-1 (IGF-1), and IMT (P = 0.42, P = 0.47 respectively). No significant differences were found in the fibrinogen, CRP and PCT levels of the acromegaly patients and the subjects in the control group (P = 0.57, P = 0.84, P = 0.68 respectively). In the patients with IMT ≥ 1 mm, PCT (0.4 [IQR: 0.4–0.55]) levels were significantly different from the patients without atherosclerosis (0.06 [IQR: 0.05–0.12], P < 0.001). The correlation between IMT and PCT (P = 0.001, r = 0.47) was more significant than the correlation between IMT and CRP (P = 0.01, r = 0.28). There was a positive correlation between IMT and atherosclerotic risk factors such as age (P = 0.01, r = 0.27) and body mass index (BMI; P = 0.005, r = 0.32). Our results showed that PCT increases before CRP and it can be useful for the assessment of premature atherosclerosis in acromegaly as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Colao A, Baldelli R, Marzullo P et al (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193–199

    Article  PubMed  CAS  Google Scholar 

  2. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, Rose K (1993) Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 6:260–270

    Google Scholar 

  3. Courville C, Mason VR (1938) The heart in acromegaly. Arch Intern Med 61:704–713

    Article  Google Scholar 

  4. Goldberg MB, Lisser H (1942) Acromegaly: a consideration of its course and treatment. Report of four cases with autopsies. J Clin Endocrinol Metab 2:477–501

    Article  Google Scholar 

  5. Hejtmancik MR, Bradfield JY, Herrmann GR (1950) Acromegaly and heart: a clinical and pathologic study. Ann Intern Med 34:1445–1456

    Google Scholar 

  6. Lie JT, Grossman SJ (1980) Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 100:41–52

    Article  PubMed  CAS  Google Scholar 

  7. Pignoli P, Tremoli E, Poli A, Paoletti R (1986) Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74:1399–1406

    Article  PubMed  CAS  Google Scholar 

  8. Mukherjee D, Yadav JS (2002) Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification. Am Heart J 144:753–759

    PubMed  Google Scholar 

  9. Salonen JT, Salonen R (1993) Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87:1156–1165

    Google Scholar 

  10. Colao A, Marzullo P, Lombardi G (2002) Effects of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146:303–309

    Article  PubMed  CAS  Google Scholar 

  11. Otsuki M, Kasayama S, Yamamoto H et al (2001) Characterization of premature atherosclerosis of carotid arteries in acromegalic patiens. Clin Endocrinol (Oxf) 54:791–796

    Article  CAS  Google Scholar 

  12. Vitale G, Pivonello R, Lombardi G, Colao A (2004) Cardiovascular complications in acromegaly. Minerva Endocrinol 29:77–88

    PubMed  CAS  Google Scholar 

  13. Wilson PW (1994) Established risk factors and coronary artery disease: the Framingham study. Am J Hypertens 7:7–12

    Google Scholar 

  14. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695

    Article  PubMed  CAS  Google Scholar 

  15. Ilhan F, Akbulut H, Karaca I, Godekmerdan A, Ilkay E, Bulut V (2005) Procalcitonin, C-reactive protein and neopterin levels in patients with coronary atherosclerosis. Acta Cardiol 60:361–365

    Article  PubMed  Google Scholar 

  16. Alexander RW (1994) Inflammation and coronary artery disease. N Engl J Med 331:468–469

    Article  PubMed  CAS  Google Scholar 

  17. Erren M, Reinecke H, Junker R et al (1999) Systemic inflammatory parameters in patients with atheroscleosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 19:2355–2363

    Article  PubMed  CAS  Google Scholar 

  18. Meisner M, Tschaikowsky K, Schnabel S, Schmidt J, Katalinic A, Schüttler J (1997) Procalcitonin–influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. Eur J Chem Clin Biochem 35:597–601

    CAS  Google Scholar 

  19. Maruna P, Nedelnikova K, Gurlich R (2000) Physiology and genetics of procalcitonin. Physiol Res 49:57–61

    Google Scholar 

  20. Giustina A, Barkan A, Casanuea FF et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529

    Article  PubMed  CAS  Google Scholar 

  21. Bastard JP, Grimaldi A, Jardel C, Porquet D, Bruckert E, Hainque B (1997) A simple index of insulin resistance. Diabetes Metab 23:87–88

    PubMed  CAS  Google Scholar 

  22. Cannavo S, Almoto B, Cavalli G et al (2006) Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 91:3766–3772

    Article  PubMed  CAS  Google Scholar 

  23. Berg C, Petersenn S, Lahner H et al (2010) Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 95:3648–3656

    Article  PubMed  CAS  Google Scholar 

  24. Bogazzi F, Battolla L, Spinelli C, Rossi G et al (2007) Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271–4277

    Article  PubMed  CAS  Google Scholar 

  25. Boero L, Manavela M, Gómez Rosso L et al (2009) Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly. Clin Endocrinol (Oxf) 70:88–95

    Article  CAS  Google Scholar 

  26. Kałuzny M, Bolanowski M, Daroszewski J, Szuba A (2010) The role of fibrinogen and CRP in cardiovascular risk in patients with acromegaly. Endokrynol Pol 61:83–88

    PubMed  Google Scholar 

  27. Potter BJ, Beauregard C, Serri O (2008) Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR. Pituitary 11:49–53

    Article  PubMed  CAS  Google Scholar 

  28. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF–1 levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87:1692–1699

    Article  PubMed  CAS  Google Scholar 

  29. Sentürk T, Cordan J, Baran I et al (2007) Procalcitonin in patients with acute coronary syndrome: correlation with high-sensitive C-reactive protein, prognosis and severity of coronary artery disease. Acta Cardiol 62:135–141

    Article  PubMed  Google Scholar 

  30. Sinning CR, Sinning JM, Schulz A et al (2011) Association of serum Procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J 75(5):1184–1191

    Article  PubMed  Google Scholar 

  31. Colao A, Spiezia S, Pivonello R et al (2001) Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 54:515–524

    Article  CAS  Google Scholar 

  32. Kartal I, Oflaz H, Pamukçu B et al (2010) Investigation of early atherosclerotic changes in acromegalic patients. Int J Clin Pract 64:39–44

    Article  PubMed  CAS  Google Scholar 

  33. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS (1994) Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 45:598–604

    Article  PubMed  CAS  Google Scholar 

  34. Böger RH, Bode-Böger SM, Mügge A et al (1995) Supplementation of hypercholesterolaemic rabbits with l-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 117:273–284

    Article  PubMed  Google Scholar 

  35. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP (1994) l-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb 14:1529–1533

    Article  PubMed  CAS  Google Scholar 

  36. Sakai H, Tsuchiya K, Nakayama C et al (2008) Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr J 55:853–859

    Article  PubMed  Google Scholar 

  37. Herrmann BL, Severing M, Schmermund A et al (2009) Impact of disease duration on coronary calcification in patients with acromegaly. Exp Clin Endocrinol Diabetes 117:417–422

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical School, University of Istanbul, Cerrahpasa Tip Fakültesi, Ic Hastalıkları Anabilim Dali, Endokrinoloji-Metabolizma ve Diyabet Bilim Dali, Cerrahpasa, 34303, Istanbul, Turkey

    H. Ozkan, O. Celik, E. Hatipoglu & P. Kadioglu

  2. Department of Radiology, Cerrahpasa Medical School, University of Istanbul, Istanbul, Turkey

    F. Kantarci

Authors
  1. H. Ozkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Hatipoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Kantarci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Kadioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Kadioglu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozkan, H., Celik, O., Hatipoglu, E. et al. Procalcitonin can be used as a marker of premature atherosclerosis in acromegaly. Pituitary 15, 358–364 (2012). https://doi.org/10.1007/s11102-011-0327-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-011-0327-y

Keywords

Search

Navigation